Farxiga’s approval for expanded use highlights potential to differentiate in HF space

AstraZeneca announced in a recent press release that Farxiga (dapagliflozin) has been approved in the US for the risk of cardiovascular death, hospitalisation for heart failure (HF), and urgent HF visits in adults with HF. Farxiga is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor previously approved for HF with reduced ejection fraction in adults. GlobalData believes that Farxiga’s approvals will help a broader range of patients with HF in the US. AstraZeneca is expected to see a significant boost in its revenues.